Company: KNRX
Filing Date: 2025-06-12
Form Type: F-1/A
Source: 0001641172-25-014801
Chunk: 75

Company: KNOREX LTD.
Filing Date: 2025-06-12
Form: F-1/A
Chunk 75
---
 SG, has agreed to transfer
all their respective preference and ordinary shares in the capital of Knorex SG to the Company. As of the date of this prospectus, the
Reorganization was completed and the Company now owns 100% of Knorex SG. In consideration thereof, the Company had allotted and issued
an aggregate of 22,477,825 Class A Ordinary Shares and 4,780,555 Class B Ordinary Shares of the Company to the shareholders of Knorex
SG and certain other persons, in accordance with and subject to the terms of the Restructuring Agreement.

Pursuant to the Restructuring
Agreement, the Company also issued warrants to shareholders of the Company, who were previously shareholders of Knorex SG, and certain
other persons in exchange for warrants previously issued to them by Knorex SG. The warrants issued by the Company included: (i) a total
of 4,692,100 warrants with an aggregate amount of US$7,722,941 and (ii) a set of warrants with an aggregate amount of US$836,597, both
exercisable for the same type of securities the Company issues in its next immediate equity financing round that involves the issuance
of preference shares or preferred securities in the Company to raise funds for the Company (or Class A Ordinary Shares if such immediate
equity financing round is our Company’s initial public offering). In January 2025, a total of 164,713 warrants described in (i) above were exercised to subscribe for 164,713 Class A Ordinary Shares with the remaining 4,527,387 warrants having been cancelled in exchange for the issuance of a total of 4,527,387 warrants with an aggregate amount of US$7,073,397.74 to extend the expiration dates to a period range from March 2026 to December 2027.The expiration dates
of the warrants described in (ii)range from December
2024 to December 2026. The exercise price for the warrants described in (ii) above with an aggregate amount of US$836,597 shall be determined
by reference to the issue price of the types of securities and shall be equal to the issue price of the securities being offered in the
next immediate equity funding round (or equal to 65% of the issue price of Class A Ordinary Shares if the next immediate equity
funding round is the Company’s initial public offering), subject to adjustment for certain dilutive events such as, among